Sirolimus-eluting Stents for High-risk Ischemic Events

This study focuses on evaluating a new type of heart stent called the Sirolimus-eluting Biodegradable Abluminal Coating Stent in patients who are at high risk for serious heart-related issues, like ischemic events, after undergoing procedures such as percutaneous coronary intervention (PCI) or coronary artery bypass surgery (CABG). These patients often have complex forms of coronary artery disease, which makes them more vulnerable to problems. The study aims to gather information about how well these stents work in reducing risks for patients with such complicated heart conditions, addressing a gap as there is limited data on this specific type of stent. Participants in this observational study will receive the Genoss stents as part of their treatment. The study will closely monitor how effective these stents are by looking at outcomes like cardiac death, heart attacks related to the treated vessels, and the need for additional procedures if the treated area narrows again. Since the study is observational, it involves watching and recording what happens to participants over time without altering their standard medical care. This approach will help determine how safe and effective the stents are in real-world settings for those with high-risk heart conditions.